Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 9/20 | 0.52 |
| ▸ | QDPR | P09417 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | KHK | P50053 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4505629 | 0.98 | SLC18A3 (0.53) | SLC18A3SIGMAR1HTR2CQDPRHTR3A | |
| SCHEMBL12045772 | 0.85 | ESR2 (0.45) | SLC6A2SLC6A4 | |
| SCHEMBL22340516 | 0.79 | SLC18A3 (0.50) | SLC18A3SIGMAR1HTR2CQDPRHTR3A | |
| SCHEMBL8483087 | 0.79 | ALDH1A1 (0.46) | SLC6A2SLC6A4 | |
| SCHEMBL5584940 | 0.78 | HTR2C (0.62) | SLC18A3SIGMAR1HTR2CQDPRKHK | |
| SCHEMBL13906346 | 0.78 | ESR2 (0.59) | SLC6A2SLC6A4 | |
| SCHEMBL82406 | 0.77 | SLC18A3 (0.61) | SLC18A3SIGMAR1HTR2CQDPRHTR3A | |
| SCHEMBL4676148 | 0.76 | SLC18A3 (0.67) | SLC18A3SIGMAR1HTR2CQDPRHTR3A | |
| SCHEMBL8317126 | 0.76 | NISCH (0.37) | SLC6A2SLC6A4 | |
| SCHEMBL20840966 | 0.76 | ESR2 (0.59) | SLC18A3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2018862-A1 | Substituted piperidines as therapeutic compounds | Speedel Experimenta AG (CH) | 2009-01-28 | — | — | EP | disclosed |
| US-7196199-B2 | Antiserotonine agents; antidepressants | MITSUBISHI PHARMA CORPORATION (JP) | 2007-03-27 | — | — | US | disclosed |
| US-20040138227-A1 | Phenoxypropylamine compounds | NISHIYAMA AKIRA | 2004-07-15 | — | — | US | disclosed |
| US-6720320-B2 | ANTISEROTONINE AGENTS | MITSUBISHI PHARMA CORPORATION (JP) | 2004-04-13 | — | — | US | disclosed |
| US-20020111358-A1 | Phenoxypropylamine compounds | MITSUBISHI PHARMA CORPORATION (JP) | 2002-08-15 | — | — | US | disclosed |
| EP-0630887-B1 | 4-(aryl-substituted)-piperidines as neurokinin receptor antagonists | ZENECA LTD (GB) | 1999-07-28 | — | — | EP | disclosed |
| US-5654299-A | TREATING RESPIRATORY SYSTEM DISORDER (I.E. ASTHMA) WITH NEUROKININ 2 RECEPTOR ANTAGONIST | ZENECA LIMITED (GB) | 1997-08-05 | — | — | US | disclosed |
| EP-0630887-A1 | 4-(aryl-substituted)-piperidines as neurokinin receptor antagonists | ZENECA LIMITED (GB) | 1994-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138227-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | SLC18A3 162/4885SIGMAR1 50/4885HTR2C 9/4885 |
| US-20020111358-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | SLC18A3 162/4885SIGMAR1 50/4885HTR2C 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.